Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.63B Buy
21,855,101
+1,308,916
+6% +$151M 0.26% 61
2025
Q4
$2.16B Buy
20,546,185
+701,249
+4% +$65.8M 0.2% 78
2025
Q3
$1.67B Buy
19,844,936
+2,821,766
+17% +$232M 0.26% 52
2025
Q2
$1.35B Buy
17,023,170
+1,725,036
+11% +$137M 0.23% 70
2025
Q1
$1.37B Sell
15,298,134
-154,106
-1% -$14.4M 0.26% 57
2024
Q4
$1.54B Buy
15,452,240
+2,847,934
+23% +$294M 0.28% 47
2024
Q3
$1.43B Sell
12,604,306
-3,192,055
-20% -$379M 0.28% 51
2024
Q2
$1.96B Sell
15,796,361
-262,178
-2% -$33.8M 0.41% 27
2024
Q1
$2.12B Sell
16,058,539
-699,071
-4% -$86.2M 0.46% 20
2023
Q4
$1.83B Sell
16,757,610
-915,207
-5% -$95M 0.43% 23
2023
Q3
$1.82B Sell
17,672,817
-3,729,753
-17% -$402M 0.49% 17
2023
Q2
$2.47B Buy
21,402,570
+2,455,377
+13% +$279M 0.65% 10
2023
Q1
$2.02B Buy
18,947,193
+1,025,444
+6% +$111M 0.56% 13
2022
Q4
$1.99B Buy
17,921,749
+270,778
+2% +$27.7M 0.58% 12
2022
Q3
$1.52B Sell
17,650,971
-1,795,320
-9% -$160M 0.49% 19
2022
Q2
$1.77B Sell
19,446,291
-600,853
-3% -$53.3M 0.54% 13
2022
Q1
$1.64B Sell
20,047,144
-153,985
-0.8% -$12.1M 0.42% 27
2021
Q4
$1.55B Buy
20,201,129
+739,839
+4% +$58.9M 0.37% 34
2021
Q3
$1.46B Buy
19,461,290
+5,687,973
+41% +$433M 0.37% 36
2021
Q2
$1.07B Buy
13,773,317
+2,013,294
+17% +$150M 0.26% 55
2021
Q1
$865M Sell
11,760,023
-4,230,246
-26% -$312M 0.23% 77
2020
Q4
$1.25B Sell
15,990,269
-251,829
-2% -$19.3M 0.36% 28
2020
Q3
$1.29B Sell
16,242,098
-973,450
-6% -$76.2M 0.43% 25
2020
Q2
$1.27B Sell
17,215,548
-1,199,056
-7% -$90.3M 0.45% 27
2020
Q1
$1.35B Sell
18,414,604
-663,647
-3% -$52.2M 0.57% 16
2019
Q4
$1.66B Sell
19,078,251
-954,295
-5% -$78.4M 0.51% 17
2019
Q3
$1.61B Buy
20,032,546
+844,569
+4% +$67.7M 0.42% 28
2019
Q2
$1.54B Buy
19,187,977
+2,979,944
+18% +$228M 0.4% 31
2019
Q1
$1.29B Sell
16,208,033
-4,682,362
-22% -$350M 0.43% 25
2018
Q4
$1.52B Sell
20,890,395
-687,430
-3% -$48.5M 0.58% 17
2018
Q3
$1.46B Buy
21,577,825
+60,755
+0.3% +$3.87M 0.46% 25
2018
Q2
$1.25B Buy
21,517,070
+1,015,262
+5% +$57.3M 0.41% 31
2018
Q1
$1.07B Buy
20,501,808
+2,141,676
+12% +$116M 0.4% 39
2017
Q4
$986M Buy
18,360,132
+1,579,341
+9% +$87.6M 0.36% 48
2017
Q3
$1.03B Sell
16,780,791
-4,675,110
-22% -$283M 0.38% 44
2017
Q2
$1.31B Sell
21,455,901
-3,791,416
-15% -$231M 0.41% 38
2017
Q1
$1.53B Sell
25,247,317
-625,314
-2% -$37.9M 0.5% 29
2016
Q4
$1.45B Buy
25,872,631
+946,179
+4% +$55.4M 0.49% 30
2016
Q3
$1.48B Sell
24,926,452
-1,465,358
-6% -$85.7M 0.51% 28
2016
Q2
$1.45B Sell
26,391,810
-551,252
-2% -$29.3M 0.53% 24
2016
Q1
$1.36B Sell
26,943,062
-1,701,341
-6% -$83.3M 0.55% 21
2015
Q4
$1.44B Buy
28,644,403
+1,739,966
+6% +$87.7M 0.58% 23
2015
Q3
$1.27B Sell
26,904,437
-120,124
-0.4% -$6.38M 0.54% 23
2015
Q2
$1.47B Buy
27,024,561
+432,487
+2% +$24.3M 0.58% 20
2015
Q1
$1.46B Buy
26,592,074
+1,032,944
+4% +$58.5M 0.56% 21
2014
Q4
$1.39B Sell
25,559,130
-616,572
-2% -$34.4M 0.54% 22
2014
Q3
$1.48B Sell
26,175,702
-264,212
-1% -$14.8M 0.59% 19
2014
Q2
$1.46B Sell
26,439,914
-783,282
-3% -$42.7M 0.57% 20
2014
Q1
$1.47B Sell
27,223,196
-3,116,933
-10% -$161M 0.6% 21
2013
Q4
$1.45B Buy
30,340,129
+1,752,037
+6% +$80.1M 0.58% 23
2013
Q3
$1.3B Sell
28,588,092
-1,334,041
-4% -$60.9M 0.56% 24
2013
Q2
$1.33B Buy
+29,922,133
New +$1.34B 0.62% 22

Other funds holding MRK

Invesco's MRK Position: Q1 2026 in Review

Invesco increased its Merck (MRK) stake by 6.4% in Q1 2026, buying an estimated $151M and bringing the position to 21,855,101 shares worth $2.63B. The position accounts for 0.26% of the portfolio, ranked #61.

Invesco first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Invesco held 21,855,101 shares of Merck worth $2.63B as of Q1 2026.
  • Invesco bought 1,308,916 Merck shares in Q1 2026, an estimated $151M.
  • Merck made up 0.26% of Invesco's portfolio in Q1 2026, its #61 holding.
  • Invesco first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.